GSK to acquire lupus drug candidate CMG1A46 for up to $850M

William Barton GSK ( NYSE: GSK ) has entered into an agreement to acquire lupus drug candidate CMG1A46 from Chimagen Biosciences for $300M upfront plus potential milestone payments of up to $550M. The U.K.

drugmaker said it plans to develop CMG1A46, a clinical-stage dual CD19 and CD20-targeted.